Kxtbio Inc., of Chapel Hill, N.C., will receive a NIH $300,000 grant to develop a new screening platform with the goal of reducing costs of the early phases of drug development. The high-throughput platform will screen for compounds acting on G protein-coupled receptors, reduce off-target hits, increase successful leads and speed up drug discovery.